Ursula Bellugi, Leading Sign Language Neuroscientist, Dies at 91

Her research showed that communication via sign language is as neurologically complex as spoken language.

Written byLisa Winter
| 3 min read
Ursula Bellugi smiling for the camera wearing a purple shirt in 2015
Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Although the origins of sign language for deaf or hearing-impaired people date back hundreds of years, its use has been highly stigmatized as being a lesser way of communicating. Neuroscientist Ursula Bellugi made significant contributions to decreasing the stigma of American Sign Language (ASL) by showing it is a complex language and not a truncated stand-in for spoken language, as some critics had described it. Bellugi died on April 17 at the age of 91.

Bellugi was born in Jena, Germany, on February 21, 1931, as Ursula Herzberger. Her father, Max, was a prominent mathematician, and her mother, Edith, was an artist. In response to Adolf Hitler’s rise to power and the dwindling prospects for Max as a Jewish scholar, the family left Germany in 1934 for upstate New York. According to The New York Times, her father’s friend and former professor, Albert Einstein, helped him get settled in Rochester ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Lisa joined The Scientist in 2017. As social media editor, some of her duties include creating content, managing interactions, and developing strategies for the brand’s social media presence. She also contributes to the News & Opinion section of the website. Lisa holds a degree in Biological Sciences with a concentration in genetics, cell, and developmental biology from Arizona State University and has worked in science communication since 2012.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies